AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27376698 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-LGI (exercise followed by a meal with low-glycemic index carbohydrates)
Number of subjects: 23
Study 27376698 — intervention group
Group type: EXPERIMENTAL
Intervention: EX-HGI (exercise followed by a meal with high-glycemic index carbohydrates)
Number of subjects: 23
Study 27376698 — intervention group
Group type: COMPARATOR
Intervention: Control (no exercise or meal)
Number of subjects: 23
Study 24679891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 314
Study 24679891 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 23750690 — intervention group
Group type: EXPERIMENTAL
Intervention: Light intensity aerobic exercise
Number of subjects: 162
Study 23750690 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous intensity aerobic exercise
Number of subjects: 162
Study 23750690 — intervention group
Group type: COMPARATOR
Intervention: Passive control condition
Number of subjects: 162
Study 20609631 — intervention group
Group type: EXPERIMENTAL
Intervention: PEARLS intervention
Number of subjects: 80
Study 20609631 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 19060427 — intervention group
Group type: EXPERIMENTAL
Intervention: Allicor (600 mg daily)
Number of subjects: 42
Study 17135784 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine hydrochloride immediate release (IR) 15 mg twice daily
Number of subjects: 988
Study 17135784 — intervention group
Group type: EXPERIMENTAL
Intervention: Propiverine hydrochloride extended release (ER) 30 mg once daily
Number of subjects: 988
Study 17135784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 988
Study 17135784 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 988
Study 12698385 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation
Number of subjects: 0
Study 12698385 — intervention group
Group type: COMPARATOR
Intervention: Inpatient rehabilitation
Number of subjects: 0
Study 10493704 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational intervention
Number of subjects: 0
Study 10493704 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 0
Study 8530597 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate
Number of subjects: 17
Study 8530597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 1936474 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 40
Study 7317248 — intervention group
Group type: EXPERIMENTAL
Intervention: guanethidine 10mg i.v.
Number of subjects: 31
Study 7317248 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study 31162005 — intervention group
Group type: COMPARATOR
Intervention: Cholera vaccine only
Number of subjects: 60000
Study 31162005 — intervention group
Group type: COMPARATOR
Intervention: Vaccine plus behavior change (cholera vaccine and handwashing plus drinking water chlorination promotion)
Number of subjects: 60000
Study 31162005 — intervention group
Group type: COMPARATOR
Intervention: Vaccine plus behavior change
Number of subjects: 60000
Study 31162005 — intervention group
Group type: COMPARATOR
Intervention: Vaccine only
Number of subjects: 60000
Study 28515547 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 100
Study 28515547 — intervention group
Group type: COMPARATOR
Intervention: Simple Advice (SA)
Number of subjects: 100
Study 25753159 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment protocol for gestational diabetes
Number of subjects: 189
Study 25753159 — intervention group
Group type: COMPARATOR
Intervention: Regular method of treatment for gestational diabetes
Number of subjects: 189
Study 23797281 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysubstance use (PSU)
Number of subjects: 3
Study 23797281 — intervention group
Group type: COMPARATOR
Intervention: Alcohol dependence (ALC)
Number of subjects: 3
Study 23797281 — intervention group
Group type: COMPARATOR
Intervention: Light drinking controls (CON)
Number of subjects: 3
Study 20660131 — intervention group
Group type: EXPERIMENTAL
Intervention: 38 per cent phosphoric acid gel
Number of subjects: 90
Study 20660131 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.6 per cent hydrofluoric acid gel
Number of subjects: 90
Study 20660131 — intervention group
Group type: EXPERIMENTAL
Intervention: Airborne aluminium trioxide particle abrasion
Number of subjects: 90
Study 20660131 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate particle abrasion
Number of subjects: 90
Study 20660131 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond bur
Number of subjects: 90
Study 20660131 — intervention group
Group type: COMPARATOR
Intervention: Control with no surface treatment
Number of subjects: 90
Study 19401377 — intervention group
Group type: COMPARATOR
Intervention: rhIGF‐I (40 microg/kg per 12h)
Number of subjects: 8
Study 19401377 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH + rhIGF‐I (50 microg/kg/d)
Number of subjects: 8
Study 16890068 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh reconstituted botulinum toxin type A (BTX‐A)
Number of subjects: 43
Study 16890068 — intervention group
Group type: COMPARATOR
Intervention: Frozen reconstituted botulinum toxin type A (BTX‐A)
Number of subjects: 43
Study 15615275 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy
Number of subjects: 227
Study 15615275 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 227
Study 15615275 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 227
Study 11465967 — intervention group
Group type: COMPARATOR
Intervention: Rauwolfia derivatives
Number of subjects: 1585
Study 11465967 — intervention group
Group type: COMPARATOR
Intervention: Diuretics
Number of subjects: 1585
Study 11465967 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 1585
Study 11465967 — intervention group
Group type: COMPARATOR
Intervention: Calcium antagonists
Number of subjects: 1585
Study 11465967 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 1585
Study 11465967 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal studies (additional five studies)
Number of subjects: 1585
Study 9213276 — intervention group
Group type: EXPERIMENTAL
Intervention: Thigh-high sequential pneumatic compression wraps
Number of subjects: 136
Study 9213276 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic foot-compression wraps
Number of subjects: 136
Study 8424297 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined thoracic epidural anaesthesia/light general anaesthesia with continuous epidural bupivacaine 10 mg.h‐1 and morphine 0.2 mg.h‐1 for 38 h after surgery plus systemic ibuprofen 600 mg x 8 h‐1
Number of subjects: 31
Study 8424297 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia and postoperative analgesia with systemic morphine and ibuprofen 600 mg x 8 h‐1
Number of subjects: 31
Study 8424297 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined thoracic epidural anaesthesia/light general anaesthesia
Number of subjects: 31
Study 8424297 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 31
Study 3117467 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin-TTS 5 mg/24 h
Number of subjects: 99
Study 3117467 — intervention group
Group type: COMPARATOR
Intervention: Long-acting nitroglycerin tablets, 10.4 mg daily
Number of subjects: 99
Study 31910658 — intervention group
Group type: EXPERIMENTAL
Intervention: DSR solution (sodium-free 10% dextrose)
Number of subjects: 0
Study 31910658 — intervention group
Group type: COMPARATOR
Intervention: Standard PD solution (Dianeal 4.25% dextrose)
Number of subjects: 0
Study 30120404 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-CHO-VE treatment
Number of subjects: 0
Study 30120404 — intervention group
Group type: EXPERIMENTAL
Intervention: FADS1 mRNA level
Number of subjects: 0
Study 27621162 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg controlled release twice a day)
Number of subjects: 32
Study 27621162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 27621162 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 32
Study 25640891 — intervention group
Group type: EXPERIMENTAL
Intervention: rhC1INH 50 IU/kg
Number of subjects: 74
Study 25640891 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 74
Study 25640891 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (rhC1INH and saline)
Number of subjects: 74
Study 23944684 — intervention group
Group type: EXPERIMENTAL
Intervention: High-caloric food supplement with high fat content
Number of subjects: 26
Study 23944684 — intervention group
Group type: EXPERIMENTAL
Intervention: High-caloric food supplement with high carbohydrate content
Number of subjects: 26
Study 21052890 — intervention group
Group type: EXPERIMENTAL
Intervention: WIF-1 expression
Number of subjects: 105
Study 21052890 — intervention group
Group type: EXPERIMENTAL
Intervention: WIF-1 methylation
Number of subjects: 105
Study 21052890 — intervention group
Group type: EXPERIMENTAL
Intervention: WIF-1 methylation and expression correlation
Number of subjects: 105
Study 19082800 — intervention group
Group type: EXPERIMENTAL
Intervention: Shengmai injection (SMI)
Number of subjects: 120
Study 19082800 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 120
Study 16562692 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 76
Study 16562692 — intervention group
Group type: COMPARATOR
Intervention: Conventional invasive synchronized intermittent mandatory ventilation (SIMV) plus pressure support ventilation (PSV)
Number of subjects: 76
Study 12821964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diet therapy (6000-7000 kJ/day or 1400-1700 kcal/day) with weekly dietitian contact for 12 weeks
Number of subjects: 51
Study 10364866 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 2.5 mg.kg‐1
Number of subjects: 32
Study 10364866 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 5 mg.kg‐1
Number of subjects: 32
Study 8894146 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg/day tibolone
Number of subjects: 94
Study 8894146 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/day tibolone
Number of subjects: 94
Study 8894146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 1825097 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous captopril
Number of subjects: 38
Study 1825097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 6301671 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (doxorubicin) 50 mg/m2 IV every three weeks
Number of subjects: 599
Study 6301671 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin (doxorubicin) 75 mg/m2 IV every three weeks
Number of subjects: 599
Study 6301671 — intervention group
Group type: COMPARATOR
Intervention: Cytoxan (cyclophosphamide)
Number of subjects: 599
Study 6301671 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin plus Cytoxan
Number of subjects: 599
Study 31454851 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological prophylaxis plus pancreatic duct stenting (group A)
Number of subjects: 414
Study 31454851 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological prophylaxis alone (group B)
Number of subjects: 414
Study 29656914 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety in Seconds v2.0TM mobile app
Number of subjects: 742
Study 26559482 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod-cream followed by intradermal trivalent influenza vaccine (INF-Q-ID)
Number of subjects: 160
Study 26559482 — intervention group
Group type: COMPARATOR
Intervention: Topical aqueous-cream control followed by intradermal trivalent influenza vaccine (INF-C-ID)
Number of subjects: 160
Study 26559482 — intervention group
Group type: COMPARATOR
Intervention: Topical aqueous-cream control followed by intramuscular trivalent influenza vaccine (INF-C-IM)
Number of subjects: 160
Study 26559482 — intervention group
Group type: COMPARATOR
Intervention: Topical imiquimod-cream followed by intradermal normal-saline injection (SAL-Q-ID)
Number of subjects: 160
Study 24190691 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years parent-training group (10-week program)
Number of subjects: 273
Study 22611089 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (SPP)
Number of subjects: 198
Study 22611089 — intervention group
Group type: COMPARATOR
Intervention: Solution-focused therapy (SFT)
Number of subjects: 198
Study 19596446 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal psycho-educational intervention
Number of subjects: 377
Study 19596446 — intervention group
Group type: COMPARATOR
Intervention: Usual care condition (control)
Number of subjects: 377
Study 18519821 — intervention group
Group type: EXPERIMENTAL
Intervention: Early detection (ED) system implemented in one health care area
Number of subjects: 231
Study 18519821 — intervention group
Group type: COMPARATOR
Intervention: No early detection (no-ED) area
Number of subjects: 231
Study 15815777 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical closure of ASD
Number of subjects: 91
Study 15815777 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter closure of ASD (Amplatzer occluder)
Number of subjects: 91
Study 12094862 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐100 mg/day prednisolone equivalent, tapered to 10‐15 mg/day within 6 weeks and maintained for another 4 weeks
Number of subjects: 300
Study 12094862 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid resistant patients
Number of subjects: 300
Study 12094862 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial CDAI in resistant patients
Number of subjects: 300
Study 9685127 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 40 infusion for 72 hours after surgery
Number of subjects: 244
Study 9685127 — intervention group
Group type: COMPARATOR
Intervention: No dextran 40 infusion
Number of subjects: 244
Study 8600180 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pilocarpine (P)
Number of subjects: 2
Study 8600180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 2782505 — intervention group
Group type: EXPERIMENTAL
Intervention: Social influences curriculum in program schools (six core and two maintenance sessions in grade 6, two booster sessions in grade 7, and one booster session in grade 8)
Number of subjects: 22
Study 2782505 — intervention group
Group type: EXPERIMENTAL
Intervention: Students who had left school
Number of subjects: 22
Study 2782505 — intervention group
Group type: EXPERIMENTAL
Intervention: Grade 6 smoking experience and social risk
Number of subjects: 22
Study 4430473 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa treatment
Number of subjects: 6
Study 29516305 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-emitting diode therapy (LEDT)
Number of subjects: 8
Study 29516305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 27725885 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition claims (healthy, diet, hedonic)
Number of subjects: 352
Study 27725885 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 352
Study 27725885 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 352
Study 25338995 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong intervention (8-week duration)
Number of subjects: 197
Study 25338995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (aerobic)
Number of subjects: 197
Study 25338995 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 197
Study 22461242 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial lipopolysaccharide (LPS; 0.4 ng/kg)
Number of subjects: 18
Study 22461242 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 18
Study 20578383 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous electroacupuncture at Neiguan (PC 6)
Number of subjects: 56
Study 20578383 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine
Number of subjects: 56
Study 18536865 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon (3 microg/mm²)
Number of subjects: 108
Study 18536865 — intervention group
Group type: COMPARATOR
Intervention: Uncoated balloon
Number of subjects: 108
Study 18536865 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated balloon
Number of subjects: 108
Study 16835738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve root infiltration guided by a nerve stimulator (n = 57)
Number of subjects: 96
Study 16835738 — intervention group
Group type: COMPARATOR
Intervention: Nerve root infiltration without nerve stimulator (n = 39)
Number of subjects: 96
Study 16835738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve root infiltration (overall)
Number of subjects: 96
Study 16835738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve root infiltration with nerve stimulator
Number of subjects: 96
Study 16835738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve root infiltration guided by a nerve stimulator
Number of subjects: 96
Study 16835738 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve root infiltration
Number of subjects: 96
Study 12789172 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelaic acid (15%) gel
Number of subjects: 664
Study 12789172 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 664
Study 11390165 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide
Number of subjects: 0
Study 11390165 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 9136139 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiocassette tape
Number of subjects: 86
Study 9136139 — intervention group
Group type: COMPARATOR
Intervention: Verbal and written instruction combined with biofeedback
Number of subjects: 86
Study 7942260 — intervention group
Group type: EXPERIMENTAL
Intervention: Fincoid-350 Short
Number of subjects: 0
Study 7942260 — intervention group
Group type: COMPARATOR
Intervention: Fincoid-350 Standard
Number of subjects: 0
Study 2884152 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 40 mg once daily
Number of subjects: 70
Study 2884152 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg twice daily
Number of subjects: 70
Study 2884152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 2266679 — intervention group
Group type: COMPARATOR
Intervention: Aluminum hydroxide gel (Al[OH]3) (5 ml) alone
Number of subjects: 10
Study 2266679 — intervention group
Group type: EXPERIMENTAL
Intervention: Al[OH]3 (5 ml) plus calcium acetate (Ca acetate) (1330 mg)
Number of subjects: 10
Study 2266679 — intervention group
Group type: EXPERIMENTAL
Intervention: Al[OH]3 (5 ml) plus calcium citrate (Ca citr) (950 mg)
Number of subjects: 10
Study 961459 — intervention group
Group type: EXPERIMENTAL
Intervention: Penfluridol
Number of subjects: 0
Study 961459 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiothixene
Number of subjects: 0
Study 961459 — intervention group
Group type: COMPARATOR
Intervention: Control (previous neuroleptics)
Number of subjects: 0
Study 31604139 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) programme
Number of subjects: 15856
Study 31604139 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) programme for lower-risk patients
Number of subjects: 15856
Study 31604139 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) programme for higher-risk patients
Number of subjects: 15856
Study 26556778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (completed EORTC QLQ-C30 and LC13 with feedback)
Number of subjects: 138
Study 26556778 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention group (completed questionnaire at baseline without feedback)
Number of subjects: 138
Study 26556778 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not complete the questionnaire)
Number of subjects: 138
Study 26452399 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE-13
Number of subjects: 52
Study 26452399 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE-15
Number of subjects: 52
Study 26452399 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE-17
Number of subjects: 52
Study 26452399 — intervention group
Group type: EXPERIMENTAL
Intervention: RPE-19
Number of subjects: 52
Study 24274323 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber snacks (10-12 g dietary fiber per day)
Number of subjects: 81
Study 24274323 — intervention group
Group type: COMPARATOR
Intervention: Usual snacks
Number of subjects: 81
Study 21262918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (FOS) 15 g/day for 4 weeks
Number of subjects: 103
Study 21262918 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-prebiotic) for 4 weeks
Number of subjects: 103
Study 21262918 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (FOS)
Number of subjects: 103
Study 21262918 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-prebiotic)
Number of subjects: 103
Study 19136677 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention including physical activity, advice on healthy food intake, and social awareness activities for 15 months.
Number of subjects: 839
Study 19136677 — intervention group
Group type: COMPARATOR
Intervention: Control group (no health education intervention).
Number of subjects: 839
Study 17439761 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-mastectomy radiation (PMRT)
Number of subjects: 0
Study 15338493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral oriented self-management training with spouse participation
Number of subjects: 59
Study 15338493 — intervention group
Group type: COMPARATOR
Intervention: Control condition (only the patient participated)
Number of subjects: 59
Study 11433992 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal rehabilitation program (Kehlet's method)
Number of subjects: 22
Study 9738607 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalist with cardiologist consultation
Number of subjects: 1716